closedosingdownloadefficacymoasafetytable-checktable-cross

The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

OTEZLA OFFERS EFFICACY IN DMARD-NAÏVE PATIENTS1

OTEZLA monotherapy reduces tender and swollen joint count in DMARD-naïve patients1,a

aPALACE 4 study. Data as observed; includes all patients who received OTEZLA 30 mg BID, regardless of whether they were initially randomized to OTEZLA 30 mg BID or placebo patients who were re-randomized to OTEZLA at week 16 or week 24. Randomized patients who received ≥1 dose of study medication: OTEZLA 30 mg BID, n = 176; placebo, n = 176. The n at each time point represents the number of patients with available data at the time point.

OTEZLA EFFECTIVELY RELIEVES PREEXISTING DACTYLITIS AND ENTHESITIS IN DMARD-NAÏVE PATIENTS1*

  • At 4 years, among patients receiving OTEZLA, 80.9% achieved resolution of dactylitis and 64% achieved resolution of enthesitis
  • During the placebo-controlled phase, at week 16, percent change in dactylitis count was -69.2% with OTEZLA 30 mg BID vs -50.0% for placebo (P = 0.1494); percent change in MASES (enthesitis) score was -50% vs 0%, respectively (P = 0.0006)

*Patients with enthesitis and dactylitis at baseline: OTEZLA 30 mg BID, 63.1% (111/176) and 47.7% (84/176), respectively; placebo, 65.3% (115/176) and 51.1% (90/176), respectively.

Data as observed.

BID, twice daily; DMARD, disease modifying antirheumatic drug; MASES; Maastricht Ankylosing Spondylitis Enthesitis Score; PALACE, Psoriatic Arthritis Long-Term Assessment of Clinical Efficacy.

Reference:

  1. Wells A, Edwards CJ, Kivitz A, et al. Long-term (4-year) efficacy and safety of apremilast monotherapy in DMARD-naïve subjects with active-psoriatic arthritis. Presented at: the 2017 ACR/ARHP Annual Meeting; November 3-8, 2017; San Diego, CA.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 51 Countries
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Singapore

  • Kuwait

  • Taiwan

  • UAE

  • Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil